2,5-bis(isopropyl)thiophene | 147871-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2,5-bis(isopropyl)thiophene
• 英文别名: 2,5-diisopropylthiophene；2,5-Diisopropylthiophen；2,5-diisopropyl-thiophene；2,5-Diisopropyl-thiophen；Thiophene, 2,5-diisopropyl；2,5-di(propan-2-yl)thiophene
• CAS: 147871-89-4
• 化学式: C₁₀H₁₆S
• 分子量: 168.303
• InChiKey: BKGQPNIFUWWNOA-UHFFFAOYSA-N

物化性质

• 沸点：
  206.1±9.0 °C(Predicted)
• 密度：
  0.939±0.06 g/cm3(Predicted)
• LogP：
  4.574 (est)
• 保留指数：
  1147

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,5-bis(isopropyl)thiophene 在 AlSi 作用下， 生成 噻吩 、 2-异丙基噻吩
  参考文献：
  名称：

  Mashkina; Chernov, Petroleum Chemistry, 2005, vol. 45, # 3, p. 209 - 215

  摘要：

  DOI：
• 作为产物：
  描述：

  3,6-bis(isopropyl)-1,2-dithiin 以100%的产率得到2,5-bis(isopropyl)thiophene
  参考文献：
  名称：

  1,2-Dichalcogenins: Simple Syntheses of 1,2-Diselenins, 1,2-Dithiins, and 2-Selenathiin

  摘要：

  Ring opening of titanacyclopentadienes 1 with (SCN)2 or (SeCN)2 followed by bis(thiocyanate) or bis(selenocyanate) cyclization affords 1,2-dithiin (2 a) or 1,2-diselenin (2 b), respectively. Compound 1 gives 2 a directly on reaction with S2 Cl2 . Unsubstituted 1,2-diselenin is prepared by reaction of PhCH2 SeNa with 1,4-bis(trimethylsilyl)-1,3-butadiyne followed by reductive cleavage of the benzyl group and oxidation. The unsubstituted 2-selenathiin is prepared in an analogous manner, but from a mixture of PhCH2 SeNa and PhCH2 SNa.

  DOI：

  10.1002/(sici)1521-3773(19990601)38:11<1604::aid-anie1604>3.0.co;2-i

文献信息

• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100317568A1

  公开（公告）日：2010-12-16

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
  申请人：CAYMAN CHEMICAL COMPANY, INC.

  公开号：US20160060216A1

  公开（公告）日：2016-03-03

  Disclosed herein are compounds of formula (I) wherein L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification. Compounds of formula (I) are EP 4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

  披露了公式(I)的化合物 其中L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 ，和s如说明书所定义。 公式(I)的化合物是EP 4 激动剂，用于治疗青光眼、骨质疏松症、骨折、牙周骨丢失、矫形植入物、脱发、神经性疼痛和相关的疾病。 还描述了药物组合物和治疗条件或疾病的方法。
• POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：CLARK Ryan

  公开号：US20110082164A1

  公开（公告）日：2011-04-07

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

  本文描述了一些作为赖氨酸磷脂酸受体拮抗剂的化合物。还描述了包括本文描述的化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物结合，用于治疗依赖或介导赖氨酸磷脂酸的疾病或病症。
• BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
  申请人：Kuo Gee-Hong

  公开号：US20070244094A1

  公开（公告）日：2007-10-18

  The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

  该发明涉及一种化合物，其化学式为（I），可用作PPAR激动剂。还描述了使用该发明的化合物治疗糖尿病、肾病、神经病、视网膜病变、多囊卵巢综合征、高血压、缺血、中风、肠易激综合征、炎症、白内障、心血管疾病、代谢X综合征、高LDL胆固醇血症、血脂异常（包括高甘油三酯血症、高胆固醇血症、混合性高脂血症和低HDL胆固醇血症）、动脉粥样硬化、肥胖以及其他与脂质代谢和能量稳态并发症相关的疾病的药物组合物和治疗方法。
• [EN] EIF4E INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EIF4E ET LEURS UTILISATIONS
  申请人：PIC THERAPEUTICS INC

  公开号：WO2021178488A1

  公开（公告）日：2021-09-10

  The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

  本发明提供了抑制elF4E活性的化合物以及使用它们的组合物和方法。